Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress
May 09, 2016 07:30 ET
|
Karyopharm Therapeutics
Phase 2/3 SEAL Clinical Trial Initiated with Selinexor for Treatment of Liposarcoma First-in-Human Study Initiated with Second-Generation SINE™ Compound KPT-8602 in Multiple Myeloma Phase 2...
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016
May 02, 2016 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016...
Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
April 20, 2016 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of...
Karyopharm to Present at the 15th Annual Needham Healthcare Conference
April 05, 2016 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus
March 31, 2016 08:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the...
Karyopharm to Present Data on Oncology Pipeline at the 2016 American Association for Cancer Research Annual Meeting
March 16, 2016 16:59 ET
|
Karyopharm Therapeutics
Two Late-Breaking Posters Featuring the Company’s Lead Drug Candidate, Selinexor (KPT-330), and Second Generation SINE Compound KPT-8602 Seventeen Additional Poster Presentations Highlighting Key...
Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress
March 14, 2016 07:30 ET
|
Karyopharm Therapeutics
Company Continues to Expand its Leadership in SINETM-based Therapies with Selinexor Clinical Advancement and Presentations of Encouraging Data for Earlier Stage Pipeline Programs Cash Expected to...
Karyopharm to Report Fourth Quarter and Full Year 2015 Financial Results on March 14, 2016
March 07, 2016 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full...
Karyopharm’s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
March 04, 2016 07:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., March 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the publication of results from a Phase 1...
Karyopharm to Present at the Leerink Partners 5th Annual Global Healthcare Conference
February 03, 2016 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...